Varicose Veins Treatment Segmentation
Treatment Type (Endovenous Ablation, Sclerotherapy, Surgical Ligation/Stripping)
Based on treatment type, the endovenous ablation segment is projected to hold the highest share of 39.2% in the varicose veins treatment market during the forecast period, further accounting for USD 6.1 billion owing to higher clinical consequences and cost-efficiency. For instance, the availability of wavelength laser is readily available in 1470nm, displaying an estimated 92.8% efficacy rates for five years in comparison to 78.5% for radiofrequency. Besides, it is estimated that there will be a 44% growth in the adoption, which is highly driven by NHI reimbursement policies, especially curated for outpatient procedures, thus driving the market growth.
Product (Venous Closure Devices, Laser Systems, Surgical Staplers)
Based on product, the venous closure devices segment is expected to hold the second-highest share of 28.8% in the varicose veins treatment market by the end of 2037. The existence and accessibility of venous closure devices such as Medtronic’s VenaSeal is poised to generate USD 4.5 billion by the end of the forecast period, which is further fueled by 45.8% of the U.S. Medicare coverage expansion, as stated in the 2025 CMS report. Besides, the biodegradable adhesive sub-segment is also projected to experience extension with a growth rate of 12.6% through approvals received from EU MDR. Also, there is a chance that surgical staples will undergo a 3.4% reduction amid ASC preference for non-invasive treatment options.
End User (Ambulatory Surgical Centers (ASCs), Hospitals, Specialty Clinics)
Based on end user, the ambulatory surgical centers (ASCs) segment is estimated to account for a share of 23.8% in the varicose veins treatment market during the forecast timeline. This segment has the capability to provide care to almost 8.8 million patients every year by the end of 2037, thereby saving almost USD 1,250 per procedure in hospitals, as stated in the 2025 AHRQ report. Besides this, the segment is expected to grab 65.5% of varicose vein treatment procedures for Germany’s outpatient policy mandates by 2030. Therefore, with this facility, hospitals will be able to retain 30.3% for complicated CVI cases, but will eventually undergo a 17.5% decline in volume yearly.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
Product |
|
|
End User |
|
|
Disease Stage |
|
|
Sclerotherapy Agent |
|
